Intrinsiq Materials leads €1.3M PROCID programme to develop copper ink for medical devices
The PROCID programme will run to the end of 2013 and is designed to prove the cost effective use of printed copper in low cost antibody based biosensors for disease detection, initially targeting the STD’s Chlamydia and Gonorrhea.
The consortium consists of distinguished specialist partners – Leeds University, ELISHA Systems Ltd, The Ryedale Group, The Needham Group, Amies Innovations and P1 Technology, with Intrinsiq Materials leading the programme and providing their novel copper ink technology. Intrinsiq Materials is an advanced materials company with facilities in Farnborough UK and Rochester US, providing nanoparticle based copper ink formulations for printed electronics applications. Intrinsiq’s copper inkjet ink, ‘Intrinsiq CI’, and copper screen print paste, ‘Intrinsiq CP’, are innovative ink formulations designed for photonic curing at room temperature in air, by laser or broad band flash techniques. Conductivities are comparable to commercial silver inks on a range of substrates, including PET and paper. The company has additional inks under development, including nanoparticle based nickel and silicon. ‘Intrinsiq CP’ copper screen print ink along with ‘Intrinsiq CI’ copper inkjet ink, are the first in a range of novel conductive inks, with additional inks under development that will ultimately see the launch of nanoparticle nickel, silicon and other formulations in the future.
Visit Intrinsiq Materials at www.intrinsiqmaterials.com
If you enjoyed this article, you will like the following ones: don't miss them by subscribing to :
